Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 4/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920371 | 0.76 | — | — | |
| SCHEMBL9920331 | 0.73 | MAP4K4 (0.37) | EPHB3MAP4K4LCKKDM4ENPC1 | |
| SCHEMBL1160390 | 0.71 | CDK2 (0.49) | EPHB3MAP4K4RIPK2LCKDRD4 | |
| SCHEMBL9920347 | 0.71 | JAK1 (0.47) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920334 | 0.70 | JAK1 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920333 | 0.70 | JAK1 (0.58) | LCKKDM4EALDH1A1JAK2JAK1 | |
| SCHEMBL9920341 | 0.70 | JAK1 (0.58) | LCKKDM4EALDH1A1JAK2JAK1 | |
| SCHEMBL9920346 | 0.69 | JAK1 (0.43) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920380 | 0.69 | — | — | |
| SCHEMBL12493142 | 0.69 | EPHB3 (0.49) | EPHB3RIPK2LCKDRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | EPHB3 3982/4885MAP4K4 79/4885RIPK2 106/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | EPHB3 4351/4885MAP4K4 48/4885RIPK2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.